Furthermore, it was discovered that glucose-induced GLP-1 secretion is decreased in patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) [35]. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.